Romidepsin (FK228, Depsipeptide)

Catalog No.S3020 Synonyms: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 157 In stock
USD 477 In stock
USD 697 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
Features More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Targets
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
In vitro

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 MX;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NVfYUIV{Oi53LUG1JI5O NGf3SWk4OiCq NYXVfZlDcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= M375bVI2PzlyOUC3
U2932  MWfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFmyeokzNjVvMUWgcm0> M3;QSlczKGh? M{fBTolv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? M3;0Z|I2PzlyOUC3
OCI-LY7 MWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mm\qNk42NTF3IH7N MXu3NkBp MnLubY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NFrh[JMzPTd7MEmwOy=>
Farage NUC4NXVtS2WubDDWbYFjcWyrdImgRZN{[Xl? NYS1e25COi53LUG1JI5O M2e4OlczKGh? M1XZ[olv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NYTCPGl{OjV5OUC5NFc>
LY7/EBV MnThR4VtdCCYaXHibYxqfHliQYPzZZk> MYGyMlUuOTVibl2= MWq3NkBp Moq5bY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NEfSNoMzPTd7MEmwOy=>
U2932/EBV NITxVmxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NUjlVGdKOi53LUG1JI5O M3z3[VczKGh? MXPpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MW[yOVc6ODlyNx?=
HCT116 NYO5[Zo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{X4NVUuPTByMDDuUS=> MlfBNlQhcA>? M2HTWGROW09? NH[4c2pqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> MWGyOVQ6OjVzNR?=
ACH-2 NEHYWY9HfW6ldHnvckBCe3OjeR?= M3TpW|EuQSCwTR?= MoHkNlQhcA>? M{HnW4lv\HWlZYOgTGlXNTFiRX72JIV5eHKnc4Ppc44> M1HLb|I2OTR7NE[3
MCF-10A Mn2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[yR2lEPTB;MD6xO:KyOC5yMTDuUS=> M3fMWVI1QTV2OEW2
MCF-7 NEXIZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonBTWM2OD1zLkGwxtExNjJyIH7N MmXLNlQ6PTR6NU[=
SK-BR-3 NWjtc21iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVG4WXhCUUN3ME2xMlAxyrFyLkO1JI5O NXq0c|U6OjR7NUS4OVY>
MDA-MB-231 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXrTYY5UUN3ME2wMlY5yrFyLkG0JI5O NXm0OI57OjR7NUS4OVY>
PC3 NXm3No1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\FeWlEPTB;MT62OeKyOC5|NTDuUS=> NHnXXYozPDl3NEi1Oi=>
HCT116 NUW0UYJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHaNnVKSzVyPUGuNFDDuTBwMECgcm0> NF7nc4UzPDl3NEi1Oi=>
HCT116-p21-/- M4nkNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MormTWM2OD1zLkK2xtExNjN5IH7N NV3aZ|lpOjR7NUS4OVY>
S1 M1y1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfiXFJRUUN3ME23MlY4yrFyLkK5JI5O M1TBXlI1QTV2OEW2
SW620 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwOURCtVAvOjlibl2= MUSyOFk2PDh3Nh?=
LOX-IMVI NHvyO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrNTWM2OD1yLki3xtExNjB|IH7N MnvRNlQ6PTR6NU[=
UACC-62 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTiUZNGUUN3ME2wMlU3yrFyLkG2JI5O MUCyOFk2PDh3Nh?=
MDA-MB-435 NYXI[lM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvLTWM2OD1yLkmwxtExNjB4IH7N NF[3WnMzPDl3NEi1Oi=>
SF-295 M2X2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{noTGlEPTB;MD64POKyOC5zNTDuUS=> NIX6cJkzPDl3NEi1Oi=>
A549 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXLSJZKSzVyPUGuNlbDuTBwMkSgcm0> NHz0ZWkzPDl3NEi1Oi=>
H460 MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDuTWM2OD1{LkW4xtExNjhyIH7N M17kWFI1QTV2OEW2
EKVX M4jYNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTFwM{RCtVAvOzRibl2= M{\nT|I1QTV2OEW2
H146 M{fzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwMkNCtVAvODdibl2= NXjxcJJiOjR7NUS4OVY>
H526 NVe0NodkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\rNmlEPTB;MD6xOeKyOC5yMzDuUS=> NHj5ZZEzPDl3NEi1Oi=>
HuT-78 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInMZpFKSzVyPUGuO|PDuTBwNESgcm0> M1zJW|I1QTV2OEW2
HA M1XQcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnCbJpEOC54MkWtNVBvVQ>? NFTOOVE1QCCq MnrTbY5lfWOnczDhJJNq\26rZnnjZY51dHlic4Tyc45o\XJiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[29vdILlZZRm\CC5aYToJIJwenSnen;tbYI> MXuyOFc4OTVzMB?=
MS-275 M17RXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULkbnBnOC54MkWtNVBvVQ>? MmXqOFghcA>? Mn;3bY5lfWOnczDhJJNq\26rZnnjZY51dHlic4Tyc45o\XJiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[29vdILlZZRm\CC5aYToJIJwenSnen;tbYI> NEnXeJAzPDd5MUWxNC=>
CD4 T M2jCTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rKfVQ5KGh? MV;FR|UxRTRwNdMxNU4xKG6P NInHW20zPDd{MkS1OC=>
CD4 T M4jDbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4faRlQ5KGh? M1jvNWNEPTB;MUC3xtEyOjZibl2= NWfYWWliOjR5MkK0OVQ>
CD4+ T NYrHOYlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnvepRITUN3ME2zJI5O NUPnb4hmOjR2OUWxNFU>
A549 NES0VpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1yxNlEx6oDVMUCwxsBvVQ>? MYiyOE8{Pi92ODDo NF24VmFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NFfOVIUzPDR6NUe5PS=>
JJN3 NGDSWHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrZNlQwPDhiaB?= NGjERndGSzVyPEJihKlvVTtiNElihKlp M2TuRVI1ODNyMUWw
OPM-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVuyOE81QCCq M4PkbWVEPTC|PUJihKlvVTtiNElihKlp MkX1NlQxOzBzNUC=
RPMI-8226 NVTY[ZZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTKNlQwPDhiaB?= NHfpS3ZGSzVyc{2xMljjiImwTUugOFjjiImq M2ruO|I1ODNyMUWw
U266 NFHuTFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\Nd|I1NzR6IHi= NWDGV4ppTUN3MIO9NVDjiImwTUugOFjjiImq NELHXFkzPDB|MEG1NC=>
CA46 MoDPRZBweHSxc3nzJGF{e2G7 MXi2JIg> M1vFSolv\HWlZYOgZox2dnRiYYDvdJRwe2m| NVrOclNmOjN7Nk[xOlQ>
DG75 MYDBdI9xfG:|aYOgRZN{[Xl? Mkf3OkBp MojTbY5lfWOnczDuc{BieG:ydH;zbZM> MnzSNlM6PjZzNkS=
Ramos MVPBdI9xfG:|aYOgRZN{[Xl? M3zaUlYhcA>? M1[4Volv\HWlZYOg[Zh1\W6|aY\lJIFxd3C2b4Ppdy=> NEfQPYUzOzl4NkG2OC=>
ST486 MWjBdI9xfG:|aYOgRZN{[Xl? NWfnWGhwPiCq MVvpcoR2[2W|IHX4eIVve2m4ZTDhdI9xfG:|aYO= M1HDXVI{QTZ4MU[0
HuT78 MW\BdI9xfG:|aYOgRZN{[Xl? Mm\INU8yOC9zMECgcm0> NFTmbpI1QCCq MYfpcoR2[2W|IHHwc5B1d3OrczDheEAyKG6P MmDuNlM2OzJ5M{K=
DpVp35 M1XWN2Fxd3C2b4Ppd{BCe3OjeR?= NH6zRnoyNzFyL{GwNEBvVQ>? NWn1UIl4PDhiaB?= NF3sd3ZqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= NIX0TnMzOzV|MkezNi=>
DpVp50 NIS5XXhCeG:ydH;zbZMhSXO|YYm= NEnO[mcyNzFyL{GwNEBvVQ>? MV20PEBp NHLyboVqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= NY\oU257OjN3M{K3N|I>
DpP75  MmDvRZBweHSxc3nzJGF{e2G7 M3Plc|EwOTBxMUCwJI5O NWDLN5FXPDhiaB?= MlvRbY5lfWOnczDicJVvfCCjcH;weI9{cXN? MUeyN|U{Ojd|Mh?=
SKOV-3 NXfxSW9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUGx5qCUOjCwTR?= MkLlO|IhcA>? MV;EUXNQ Mln1doVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> MVmyN|AyODN2OB?=
Brca1 WT Moi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnsfXUy6oDVMkDuUS=> NGq3XII4OiCq M2jQSGROW09? M3TaO5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv NXPHNm82OjNyMUCzOFg>
Brca1 Null NELmfGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XvbFHjiJN{MH7N MV[3NkBp NFywTmJFVVOR NVHtOJNHemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? Mn3FNlMxOTB|NEi=
OVCAR-8  MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPqdHFlOeLCk{Kwcm0> MoPWO|IhcA>? Ml;6SG1UVw>? MVXy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> M{[0bVI{ODFyM{S4
NCI/ADR-RES MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX2x5qCUOjCwTR?= NXjDV3pjPzJiaB?= NWH6fmhDTE2VTx?= M{jkTpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv NITHTmMzOzBzMEO0PC=>
HCT116 NW\XbVdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7jNVVrPSCwTT21NEDPxE1? MYWyOEBp MmnoSG1UVw>? NXTHPHNDcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? M3X5XFIzQTJ2OUW4
RKO M3fXWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGP1RZc2KG6PLUWwJO69VQ>? NHT2ZXozPCCq NF\mOHBFVVOR NV;vbW1VcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? MUCyNlkzPDl3OB?=
CO115 NH\vbpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUm1JI5ONTVyIN88US=> NGXQU|AzPCCq NEO4cJFFVVOR NYf3O3pVcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? NWfOUZJmOjJ7MkS5OVg>
HFS NWXCPWxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYC1JI5O NVrK[FNPOjRxNEivO|IhcA>? MUnpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nLXTldIVv\GWwdHz5 M2HYUVIzOTB4Mkiy
LNCaP MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfET5I2KG6P NWiyV5hHOjRxNEivO|IhcA>? NIX0S|dqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 NFTVVo0zOjFyNkK4Ni=>
A549 M3nKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzOe|BsPSCwTR?= M1jlZ|I1NzR6L{eyJIg> Mm\wbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> M1PkTVIzOTB4Mkiy
697  NYTtNGc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvsSWpKSzVy4pEJQgKBkTJwNdMgcm0> NVyxOVc5OjF3M{iyNVY>
697-R NIjVN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|Ux6oDLPfMAjVgvPsLibl5CpC=> MVWyNVU{QDJzNh?=
HUT78 NFzOOnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfoTWM2OD1zIH7N NEjiTYszOTF7OEW0OS=>
THJ-16T NYLTO4c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nBW|Ehdk1? NX[3NldHOjRiaB?= MoLFbY5pcWKrdIOgZ4VtdCCpcn;3eIg> M1ntRlIxQDFyNU[4
HCT116 NUPI[HFnTnWwY4Tpc44hSXO|YYm= MYCyNEBvVQ>? M2HNb|ghcA>? MlHocY9lfWyjdHXzJJRz[W6|Y4LpdJQhdGW4ZXzzJIZweiCqdX7kdoVleyCxZjDn[Y5meyCrbjDlbZRp\XJiZHny[YN1cW:w NVXCXGJiOjB5M{m0OVQ>
B104  MXHGeY5kfGmxbjDBd5NigQ>? MmLLNkBvVQ>? MlnrNlQwPDhxN{KgbC=> NGH4UYpqdmO{ZXHz[ZMhfGinIIP1doZi[2ViZYjwdoV{e2mxbjDv[kBETDJywrC= NYG1T|JSOjB4OE[1NFU>
HL-60  NYH6UGFjS3m2b4TvfIlkcXS7IFHzd4F6 NX[2b5JyOS13MECgcm0> NGjpe|UzPCCq M{Ozdolv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? MoOzNlA3OjRzNkO=
HP100 MmK1R5l1d3SxeHnjbZR6KEG|c3H5 MnntNU02ODBibl2= NELob4wzPCCq Ml[4bY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NGe0UY4zODZ{NEG2Ny=>
HL-60  NHXGcoRHfW6ldHnvckBCe3OjeR?= MnXGNVAhdk1? NVXhbI1jPC94L{G2JIg> M4GwRYlv\HWlZYOgeIhmKGenbnXyZZRqd25ib3[gbJllem:pZX6gdIVzd3irZHWg[pJwdSB2aB?= MUGyNFYzPDF4Mx?=
HP100 NIHIUIZHfW6ldHnvckBCe3OjeR?= NWL4dWcxOTBibl2= NV7jOGEzPC94L{G2JIg> M1rVUYlv\HWlZYOgeIhmKGenbnXyZZRqd25ib3[gbJllem:pZX6gdIVzd3irZHWg[pJwdSB2aB?= MVyyNFYzPDF4Mx?=
HL-60  MlHVSpVv[3Srb36gRZN{[Xl? NGHx[JMyOC13MECgcm0> MWS0JIg> MkTS[IVkemWjc3XzJJRp\SCqaYP0c45mKGSnYXPleJlt[XOnIDjISGFEMSCjY4Tpeol1gcLi MoS0NlA3OjRzNkO=
HP100 NHnwTXlHfW6ldHnvckBCe3OjeR?= MYqxNE02ODBibl2= M1PpOlQhcA>? MmK2[IVkemWjc3XzJJRp\SCqaYP0c45mKGSnYXPleJlt[XOnIDjISGFEMSCjY4Tpeol1gcLi NFvteY4zODZ{NEG2Ny=>
11z NFHye4pMcW6jc3WgRZN{[Xl? M4LnWlMuOTByIH7N MYTy[YR2[2W|IFjERWMh\W68eX3heIlkKGGldHn2bZR6KCiLQ{WwxsA:KDZwNTFCtUAxNjZibn3vcE9NMQ>? M{WyNVIxPjB3MUS0
SKOV-3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX:0M|gwOTZibl2= MXu0PEBp M1i1dIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NIm2UHQzODRyNEW2OC=>
OVCAR-3 M{DEfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWm0M|gwOTZibl2= NHXSOYY1QCCq M{faW4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NXnk[FlGOjB2MES1OlQ>
HBL-2 NETsbFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXXdZduOi1zMDDuUS=> M1PWcFI1KGh? NY\FfZFPUUN3ME20MlMhdk1? NE[5blEzODB4OEC4NC=>
Jeko-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonUNk02OCCwTR?= MXiyOEBp M4LkWmlEPTB;MUGgcm0> MXqyNFA3QDB6MB?=
Granta-519 Mo\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LuS|UuPDBibl2= M4PQWlI1KGh? NEmyUVNKSzVyPUW4MlUhdk1? M{TKPVIxODZ6MEiw
L1236 NVzDPWd3S3m2b4TvfIlkcXS7IFHzd4F6 NF[zfmUyKG6PLUGwNEDPxE1? M3T5PFQ5KGh? NF;oeIVGSzVyPUCuNFch|ryP NFvTPYUyQTJ|M{S3NC=>
L428 NUW4dpZKS3m2b4TvfIlkcXS7IFHzd4F6 MmC5NUBvVS1zMECg{txO MmfIOFghcA>? NEPydppGSzVyPUCuOFMh|ryP M1Xz[|E6OjN|NEew
KM-H2 MVXDfZRwfG:6aXPpeJkhSXO|YYm= MmDaNUBvVS1zMECg{txO Ml;uOFghcA>? NGe5VJBGSzVyPUCuOVgh|ryP NH76bIcyQTJ|M{S3NC=>
L540Cy NEfRSoFEgXSxdH;4bYNqfHliQYPzZZk> M4\xRlEhdk1vMUCwJO69VQ>? MkjiOFghcA>? MnHvSWM2OD1yLkG2JO69VQ>? MUixPVI{OzR5MB?=
G401 MVHGeY5kfGmxbjDBd5NigQ>? NYD5ZlVHOTBibl2= NFHFbJMzPC92OD:3NkBp M{DZXGROW09? M1jrT4lv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> M{\S[lE6OjJzNUi2
STM91-01 NHzXXotHfW6ldHnvckBCe3OjeR?= NGTtfVMyOCCwTR?= MoiyNlQwPDhxN{KgbC=> MknySG1UVw>? MVnpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= MoDjNVkzOjF3OE[=
SJSC  MnO1SpVv[3Srb36gRZN{[Xl? NXy1[mg1OTBibl2= MmTaNlQwPDhxN{KgbC=> NEnUO|lFVVOR MUjpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= M4\TWVE6OjJzNUi2
BT16  NG\K[2ZHfW6ldHnvckBCe3OjeR?= MXexNEBvVQ>? NXvl[FNXOjRxNEivO|IhcA>? NWmzXGR{TE2VTx?= NFPZZ3hqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> M2HtNVE6OjJzNUi2
NCI-H1299 M{PheGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3P5V2lEPTB;ND62xtExNjJibnevcYw> M1XkWVE6OTd7OEmw
NCI-2882 NFK4dodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDMN2F5UUN3ME2xMlbDuTBwMESgcocwdWx? M2mwcVE6OTd7OEmw
HCC95 Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJwNdMxNE4xPSCwZz;tcC=> NYDybXFOOTlzN{m4PVA>
NCI-H23 NV;IbXZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJwOdMxNE4zKG6pL33s M1TCV|E6OTd7OEmw
NCI-H157 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4m5V2lEPTB;MT62xtExNjB{IH7nM41t NWD1WpNCOTlzN{m4PVA>
NCI-H460 NHq2UG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkWyTWM2OD1{LkJCtVAvODdibnevcYw> M4XXbFE6OTd7OEmw
NCI-H1975 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFm3SmJKSzVyPUGuN:KyOC5yNDDu[{9udA>? NX7H[|IxOTlzN{m4PVA>
NCI-H820 NXH2VIY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LQW2lEPTB;Mj60xtExNjFibnevcYw> NHn0eWQyQTF5OUi5NC=>
NCI-H1650 NYjRVVFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jsRWlEPTB;ND65xtExNjNibnevcYw> MYOxPVE4QTh7MB?=
DTC1 NYfC[Wd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWW2cmRNUUN3ME2wMlUyKG6P MUmxPFU3PjJ2Nh?=
KAO NUHvboV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfQU|dKSzVyPUCuPVEhdk1? NEPP[2MyQDV4NkK0Oi=>
SU-CCS-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvpTWM2OD1yLki5JI5O MXmxPFU3PjJ2Nh?=
SYO-1 NVTUc|JFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPSTWM2OD1yLk[3JI5O NX7PXVNKOTh3Nk[yOFY>
FUJI MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\jSlhCUUN3ME2xMlMyKG6P MUGxPFU3PjJ2Nh?=
SKNMC NEHFRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnJU5R4UUN3ME2xMlE4KG6P M3fRNVE5PTZ4MkS2
402-91 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmK5TWM2OD1zLkK2JI5O M4DyTVE5PTZ4MkS2
1765-92 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTFwN{egcm0> NV7UdmF2OTh3Nk[yOFY>
JN-DSRCT-1 NWDHblFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfm[WxzUUN3ME2xMlI2KG6P MXixPFU3PjJ2Nh?=
NMS-2PC NXvERpd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:0TWM2OD1yLkixJI5O MUCxPFU3PjJ2Nh?=
HL60 M1fYdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoH5TWM2OD1zLki2JI5O NITNRYkyQDV4NkK0Oi=>
A549 M4fVZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHuTWM2OD1|LkK0JI5O MWSxPFU3PjJ2Nh?=
SW480 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJwNkmgcm0> NIexR2syQDV4NkK0Oi=>
MCF7 Mni1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXaUnA5UUN3ME2zMlU2KG6P M2XaNFE5PTZ4MkS2
PC-3 NWfsXlRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTJwNUGgcm0> MmPxNVg2PjZ{NE[=
MMRU M3PTXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWry[ldCUUN3ME2yMlU4KG6P MWWxPFU3PjJ2Nh?=
Hs68 NHyzb2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPUTWM2OD1-MUCgcm0> MnrZNVg2PjZ{NE[=
hMSC-001F NUm0c4hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PINWlEPTB;PkGwJI5O NVP6PZZTOTh3Nk[yOFY>

... Click to View More Cell Line Experimental Data

In vivo Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

Protocol

Kinase Assay:

[1]

+ Expand

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
Cell Research:

[3]

+ Expand
  • Cell lines: HL60, Jurkat, A549, and MCF-7
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: Male scid mice inoculated i.p. with U-937 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~1 mg/kg once or twice a week
  • Administration: Treated i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 540.7
Formula

C24H36N4O6S2

CAS No. 128517-07-7
Storage powder
Synonyms FR 901228, NSC 630176

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00048334 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2002 Phase 1
NCT00094978 Terminated Carcinoma, Small Cell|Carcinoma, Non-Small-Cell Lung|Esophageal Neoplasms|Mesothelioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 25, 2004 Phase 1
NCT01445340 Terminated Mycosis Fungoides|Cutaneous T-Cell Lymphoma|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 21, 2007 Phase 1
NCT02616965 Not yet recruiting Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics, Inc.|Celgene Corporation April 2017 Phase 1
NCT02850016 Recruiting Human Immunodeficiency Virus (HIV) Rockefeller University|University Hospital of Cologne|Aarhus University Hospital December 2016 Phase 2
NCT02757248 Withdrawn PTCL|CTCL Anne Beaven, MD|National Comprehensive Cancer Network|Boehringer Ingelheim|Duke University November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) supplier | purchase Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) cost | Romidepsin (FK228, Depsipeptide) manufacturer | order Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID